国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2014年
3期
160-163
,共4页
郭炽星%张晖燕%蒋敏慧%徐碧红%黎敬忠%罗嘉莉
郭熾星%張暉燕%蔣敏慧%徐碧紅%黎敬忠%囉嘉莉
곽치성%장휘연%장민혜%서벽홍%려경충%라가리
奈瑟球菌,淋病%微生物敏感性试验%药物监测
奈瑟毬菌,淋病%微生物敏感性試驗%藥物鑑測
내슬구균,임병%미생물민감성시험%약물감측
Neisseria gonorrhoeae%Microbial sensitivity tests%Drug monitoring
目的 监测淋病奈瑟球菌(淋球菌)对5种抗菌药物的最小抑菌浓度(MIC)和质粒介导耐药株,分析产β-内酰胺酶淋球菌(PPNG)和四环素高水平耐药淋球菌(TRNG)的流行趋势.方法 收集2008年1月至2012年12月广州市番禺区慢性病防治站确诊淋病患者中分离的淋球菌436株.采用纸片酸度法测定β-内酰胺酶,采用琼脂稀释法测定淋球菌株对大观霉素、头孢曲松、青霉素、四环素和环丙沙星的MIC.结果 436株淋球菌中,检出PPNG 147株(33.72％)和TRNG 222株(50.92％).PPNG和TRNG的阳性率波动区间分别为24.32％～45.59％和21.31％～67.57％,两者各年度的阳性率差异均有统计学意义(x2=11.659、38.464,P均＜0.05).5年间未见大观霉素和头孢曲松耐药菌株出现,但头孢曲松的中介率在26.13％～72.13％间波动,各年度的差异有统计学意义(x2=39.720,P＜0.01),两者的MIC50和MIC90均在敏感范围;青霉素、四环素、环丙沙星的MIC50和MIC90变化较大,且都超过了耐药标准,总耐药率分别为76.37％(333/436)、88.76％ (387/436)和94.26％ (411/436).结论 2008-2012年大观霉素和头孢曲松对淋球菌敏感性较好,后者虽然中介率较高,但两者仍可作为治疗淋病的首选药物;青霉素、四环素和环丙沙星MIC50和MIC90变化较大,均超过了耐药标准,提示它们已不能作为治疗淋病的主要药物.
目的 鑑測淋病奈瑟毬菌(淋毬菌)對5種抗菌藥物的最小抑菌濃度(MIC)和質粒介導耐藥株,分析產β-內酰胺酶淋毬菌(PPNG)和四環素高水平耐藥淋毬菌(TRNG)的流行趨勢.方法 收集2008年1月至2012年12月廣州市番禺區慢性病防治站確診淋病患者中分離的淋毬菌436株.採用紙片痠度法測定β-內酰胺酶,採用瓊脂稀釋法測定淋毬菌株對大觀黴素、頭孢麯鬆、青黴素、四環素和環丙沙星的MIC.結果 436株淋毬菌中,檢齣PPNG 147株(33.72％)和TRNG 222株(50.92％).PPNG和TRNG的暘性率波動區間分彆為24.32％～45.59％和21.31％～67.57％,兩者各年度的暘性率差異均有統計學意義(x2=11.659、38.464,P均＜0.05).5年間未見大觀黴素和頭孢麯鬆耐藥菌株齣現,但頭孢麯鬆的中介率在26.13％～72.13％間波動,各年度的差異有統計學意義(x2=39.720,P＜0.01),兩者的MIC50和MIC90均在敏感範圍;青黴素、四環素、環丙沙星的MIC50和MIC90變化較大,且都超過瞭耐藥標準,總耐藥率分彆為76.37％(333/436)、88.76％ (387/436)和94.26％ (411/436).結論 2008-2012年大觀黴素和頭孢麯鬆對淋毬菌敏感性較好,後者雖然中介率較高,但兩者仍可作為治療淋病的首選藥物;青黴素、四環素和環丙沙星MIC50和MIC90變化較大,均超過瞭耐藥標準,提示它們已不能作為治療淋病的主要藥物.
목적 감측임병내슬구균(림구균)대5충항균약물적최소억균농도(MIC)화질립개도내약주,분석산β-내선알매림구균(PPNG)화사배소고수평내약림구균(TRNG)적류행추세.방법 수집2008년1월지2012년12월엄주시번우구만성병방치참학진임병환자중분리적림구균436주.채용지편산도법측정β-내선알매,채용경지희석법측정림구균주대대관매소、두포곡송、청매소、사배소화배병사성적MIC.결과 436주림구균중,검출PPNG 147주(33.72％)화TRNG 222주(50.92％).PPNG화TRNG적양성솔파동구간분별위24.32％～45.59％화21.31％～67.57％,량자각년도적양성솔차이균유통계학의의(x2=11.659、38.464,P균＜0.05).5년간미견대관매소화두포곡송내약균주출현,단두포곡송적중개솔재26.13％～72.13％간파동,각년도적차이유통계학의의(x2=39.720,P＜0.01),량자적MIC50화MIC90균재민감범위;청매소、사배소、배병사성적MIC50화MIC90변화교대,차도초과료내약표준,총내약솔분별위76.37％(333/436)、88.76％ (387/436)화94.26％ (411/436).결론 2008-2012년대관매소화두포곡송대림구균민감성교호,후자수연중개솔교고,단량자잉가작위치료임병적수선약물;청매소、사배소화배병사성MIC50화MIC90변화교대,균초과료내약표준,제시타문이불능작위치료임병적주요약물.
Objective To monitor the minimum inhibitory concentration (MIC) of 5 antibiotics for Neisseria gonorrhoeae and its plasmid-mediated resistant strains,and to analyze the trend of drug resistant strains penicillinase-producing Neisseria gonorrhoeae (PPNG) and tetracycline-resistant Neisseria gonorrhoeae (TRNG).Methods Four hundred and thirty-six isolates of Neisseria gonorrhoeae were collected from Panyu Institute of Chronic Disease,Guangzhou from 2008 and 2012.The production of β-lactamase was determined by paper acidometric method.The agar dilution method was used to determine the MIC of spectinomycin,cefatriaxone,penicillin,tetracycline and ciprofloxacin.Results Out of 436 isolates,147 (33.72％) were plasmid-mediated PPNG strains and 222(50.92％) were TRNG strains.During the 5-year period,the prevalence of PPNG and TRNG ranged from 24.32％ to 45.59％ and from 21.31％ to 67.57％,with significant differences(x2=11.659,38.464,P all＜0.05).None of the strains were resistant to spectinomycin and ceftriaxone,but the ceftriaxone intermediate rate fluctuated from 26.13％ to 72.13％ with significant differences (x2=39.720,P＜0.01),and their MIC50 and MIC90 were all in the sensitive ranges.However,the MIC50 and MIC90 of penicillin,tetracycline and ciprofloxacin changed greatly,and were significantly higher than resistant standards,with the resistance rates of 76.37％ (333/ 436),88.76％ (387/436) and 94.26％ (411/436),respectively.Conclusions From 2008 to 2012,spectinomycin and ceftriaxone are both sensitive to Neisseria gonorrhoeae,and are recommended as the first-line antibiotics against gonorrhea.The MIC50 and MIC90 of penicillin,tetracycline and ciprofloxacin are unstable and rise above the resistant standards,indicating that it is inappropriate to use them as the first-line antibiotics in treatment of gonorrhea.
